Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q1 2017 · 10-Q
Revenue—
Net Income-$7.76M-$7.76MN/M vs Q1 2016 EPS Diluted-$0.05-$0.05N/M vs Q1 2016 Operating Income-$557,512N/M Operating Cash Flow-$434,192N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
ended Mar 31, 2017 · filed May 12, 2017 · 42 d after period end